Uterine fibroids
Drug research and approvals for uterine fibroids: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 43 studies of uterine fibroids are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 43
- Trials authorized in Canada: 7
- FDA orphan approvals: 0
- EU medicines: 2
Recruiting Now
Newest start dates first, of 43 recruiting on ClinicalTrials.gov ↗- Stellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic SurgeryNCT07860203 · Not applicable · Catherin Zhang · starts Oct 1, 2026
- Artificial Intelligence Into Ultrasound Diagnostics in Reproductive MedicineNCT07810920 · Not reported · Semmelweis University · starts Sep 1, 2026
- FATIMA Trial: EGCG and Vitamin D3 for Prevention of Fibroid RecurrenceNCT07647198 · Phase 2 · Sheikh Shakhbout Medical City · starts Aug 22, 2026
- Safety and Efficacy of Microwave Ablation Alone Versus Microwave Ablation Combined With Chemical Ablation in the…NCT07754877 · Not applicable · Peking University Aerospace Center Hospital · starts Aug 1, 2026
- Deep Neuromuscular Blockade and a Low-Residue Diet for the Surgical Field in vNOTES HysterectomyNCT07730970 · Not applicable · Fatih Sultan Mehmet Training and Research Hospital · starts Jul 1, 2026
- Reducing Blood Loss During Myomectomy:Uterine Artery Ligation Vs Pericervical TourniquetNCT07526311 · Not applicable · Cairo University · starts Apr 10, 2026
- Predictors of Success and Failure of v-NOTES Hysterectomy for Large and Very Large UteriNCT07895953 · Not reported · University Hospital, Strasbourg, France · starts Mar 20, 2026
- The Effect of Uterine Manipulator Use During Abdominal Hysterectomy on Postoperative Sexual FunctionNCT07431788 · Not applicable · Erkan Gol · starts Mar 2, 2026
- Phase II Study of CMS-D002 Capsule for Uterine Fibroids With MenorrhagiaNCT07402369 · Phase 2 · Shenzhen Kangzhe Biotechnology Co., Ltd. · starts Feb 19, 2026
- to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and MenorrhagiaNCT07378098 · Phase 3 · JW Pharmaceutical · starts Feb 3, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Jun 7, 2017 | A randomized, parallel-group, double-blind, double-dummy, active-controlled, multicenter study to assess the efficacy and safety of vilaprisan in subjects with…VILAPRISAN (BAY-1002670) | Bayer | Closed |
| Oct 27, 2016 | Extension study to evaluate the efficacy and safety of elagolix in premenopausal women with heavy menstrual bleeding associated with uterine fibroidsELAGOLIX (ABT-620)/ ESTRADIOL-NORETHINDRONE | AbbVie | Closed |
| Apr 29, 2016 | Treatment of uterine fibroids with magnetic resonance guided high intensity focused ultrasoundLEUPROLIDE | THUNDER BAY REGIONAL RESEARCH INSTITUTE | Pending |
| Feb 23, 2016 | A phase 3 study to evaluate the efficacy and safety of elagolix in combination with estradiol/norethindrone acetate for the management of heavy menstrual…ELAGOLIX (ABT-620)/ ESTRADIOL-NORETHINDRONE | AbbVie | Closed |
| Feb 16, 2016 | A phase 3 study to evaluate the efficacy and safety of elagolix in combination with estradiol/norethindrone acetate for the management of heavy menstrual…ELAGOLIX (ABT-620)/ ESTRADIOL-NORETHINDRONE | AbbVie | Closed |
| May 13, 2014 | A randomized, parallel-group, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of different doses of bay 1002670 in…VILAPRISAN (BAY 1002670) | Bayer | Closed |
| Jul 5, 2013 | A phase 2b study to evaluate the safety and efficacy of elagolix in premenopausal women with heavy menstrual bleeding associated with uterine fibroidsELAGOLIX (ABT-620)/ ESTRADIOL-NORETHINDRONE | AbbVie | Closed |
Medicines Authorised in the EU
Newest first| Jun 14, 2022 | Yseltylinzagolix choline | Theramex Ireland Limited | EMA ↗ |
| Jul 16, 2021 | Ryeqorelugolix;estradiol;norethisterone acetate | Gedeon Richter Plc. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA